PRL3-zumab

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NamePRL3-zumab
Drug Alias NamePRL3 ZUMAB
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProtein tyrosine phosphatase inhibitors
TargetsProtein tyrosine phosphatase
Therapy Area/IndicationsSolid tumoursMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesIntra-Immusg
China Registration ClassN/A

Develop Information

Active CompaniesIntra-Immusg Pte Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A